Bntx stocks.

Mar 2, 2022 · Although shares of biotech company BioNTech (BNTX 0.89%) have recently fallen along with most other stocks, the vaccine maker's performance over the past 12 months remains above that of the ... That comes out to about $9.97 and $4.61 billion, respectively. Both metrics topped BNTX stock analysts' forecasts, though earnings fell 24% and sales tumbled 23%.BioNTech (BNTX) stock fell ~5% premarket Aug. 8 after the company's Q2 results missed analysts estimates, however the company reaffirmed its COVID-19 vaccine revenues outlook for...BNTX Description — BioNTech SE. BioNTech develops immunotherapies for cancer and other diseases. Co.'s immunotherapy product candidates span the following four drug classes: messenger ribonucleic acid (mRNA) therapeutics, in which it is utilizing mRNA to deliver genetic information to cells; cell therapies, in which it is developing a range of cell …

Since initial coverage, BioNTech stock has lost $6 billion in value. BNTX's first quarter revenues were $5.6 billion less than 2022. People may be thinking the Covid-19 global pandemic is over.(RTTNews) - Pharmaceutical giant Pfizer Inc. (PFE) and German biotech firm BioNTech SE (BNTX) announced Wednesday that their mRNA-based COVID-19 v...If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.

BioNTech SE (BNTX) - 6-K - Report of Foreign Issuer. SEC FilingsWed, Nov. 30, 2022. Latest SEC filings for BioNTech SE (BNTX).Real-time Price Updates for Biontech Se ADR (BNTX-Q), along with buy or sell ... Why Pfizer and BioNTech Stocks Zoomed Higher Today. September 29, 2023. Motley ...

BNTX stock currently hovers slightly below $170, up 45% over the past 12 months. The stock price has declined 24.5% YTD. Shares are trading at 4.9 times forward earnings and 2.5 times trailing sales.BNTX Description — BioNTech SE. BioNTech develops immunotherapies for cancer and other diseases. Co.'s immunotherapy product candidates span the following four drug classes: messenger ribonucleic acid (mRNA) therapeutics, in which it is utilizing mRNA to deliver genetic information to cells; cell therapies, in which it is developing a range of cell …Photo by Pascal Bernardon on Unsplash. Worst Performing NASDAQ Stocks In 2023 15. BioNTech SE (NASDAQ:BNTX) Number of Hedge Fund Holders: 22. YTD Share Price Decline as of July 30: 27.74%BioNTech SE ADR. An der Goldgrube 12. Mainz, Rheinland-Pfalz 55131. Phone 49 6131 908-40. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue $18.19B.

Biopharmaceutical New Technologies or BioNTech ( NASDAQ: BNTX) is a large ($31 billion market cap) immunotherapy company. They are developing cancer product candidates (Figure 1) but known mostly ...

BNTX stock analysts projected a per-share loss of 30 cents. BioNTech blamed write-offs to partner Pfizer for the profit and sales hits. On today's stock market, BNTX stock toppled 7.5% to 98.50.

It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Aug 7, 2023 · BNTX stock analysts projected a per-share loss of 30 cents. BioNTech blamed write-offs to partner Pfizer for the profit and sales hits. On today's stock market, BNTX stock toppled 7.5% to 98.50 ... BioNTech stock (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 ...Among the 386 stocks in the Biotech industry, MRNA is ranked #62, while BNTX is ranked #27. Beyond what is stated above, we have also rated the stocks for Value, Growth, Momentum, Stability, and ...The stock opened at $102.47, slightly higher than the previous day’s closing price of $102.42. Throughout the day, the stock fluctuated within a range of $98.80 to $102.47. The trading volume for the day was 9,949. BNTX has a market capitalization of $23.2 billion and operates in the Health Technology sector and the Biotechnology industry.Jan 24, 2022 · As half of the duo behind one of the world's most widely used and effective COVID-19 vaccines, BioNTech (BNTX 1.37%) is well on its way to enduring stardom in the healthcare sector. Far from ...

609.75M. -85.76%. Get the latest BioNTech SE - ADR (BNTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ... 3. BioNTech. Per its coronavirus vaccine collaboration with Pfizer, BioNTech ( BNTX 1.40%) is the only company on this list that's currently earning revenue as a result of its sales of mRNA ...BNTX Real-Time Quotes. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and ...Charts powered by. BioNTech SE (ADR) share price in real-time (A2PSR2 / US09075V1026), charts and analyses, news, key data, turnovers, company data.Like many other biotech names, BNTX stock has fallen 30 % YTD. Shares are trading at 4.2 times forward earnings and only 1.7 times sales. At present, the 12-month median price forecast for ...What happened. Shares of BioNTech (BNTX-1.01%) were 9.1% lower as of 11:51 a.m. EDT on Thursday. The German biotech didn't report any news, so why did its stock slide? You can probably blame ...Find the latest Insider Activity data for BioNTech SE American Depositary Share (BNTX) at Nasdaq.com.

Oct 19, 2021 · BioNTech (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about ... BNTX : 99.70 (-1.00%) SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioNTech SE - BNTX PR Newswire - Tue Oct 17, 7:35PM CDT. /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX).

BNTX : 98.83 (+0.89%) SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioNTech SE - BNTX PR Newswire - Tue Oct 17, 7:35PM CDT. /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX).BioNTech SE (BNTX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock BioNTech SE | Nasdaq: BNTX | NasdaqThe Biontech Se Sponsored Adr stock price fell by -1.01% on the last day (Friday, 1st Dec 2023) from $100.41 to $99.40. During the last trading day the stock fluctuated 5.12% from a day low at $94.78 to a day high of $99.63. The price has been going up and down for this period, and there has been a -0.3% loss for the last 2 weeks.Biotechs are becoming a dominating force in the healthcare sector. Some scientists believe that we’re in the “golden age” of biotechnology. 2021 was a difficult year for biotech stocks, generally, despite many of those trading at dirt-cheap valuations that don't even reflect the cash they have in hand. It was expected that Biotechs would performBNTX Stock 12 Months Forecast. $132.67. (38.52% Upside) Based on 12 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $132.67 with a high forecast of $184.00 and a low forecast of $100.00. The average price target represents a 38.52% change from the last price of $95.78.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...BNTX : 98.83 (+0.89%) SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioNTech SE - BNTX PR Newswire - Tue Oct 17, 7:35PM CDT. /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX).You can buy and sell BioNTech SE (BNTX) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details.However, it's significantly underperforming BNTX stock's YTD return of 258.1%. What was Moderna's FY22 Outlook Presented in FQ3? Moderna presented a reasonably strong FY22 guidance in its FQ3 ...

Of the 299 institutional investors that purchased BioNTech stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Temasek Holdings Private Ltd ($3.98M), Baillie Gifford & Co. ($2.54M), Flossbach Von Storch AG ($2.45M), Artisan Partners Limited Partnership ($2.19M), Envestnet Asset ...

BioNTech (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock rally from about $80 at the end of 2020 to levels of almost $420 currently ...

For example, BioNTech SE’s (NASDAQ:BNTX) stock was trading in the $20s at the start of 2020, but by the end of the year, ... Top 10 Growth Stocks in Biotech 10.BNTX : 99.70 (-1.00%) SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioNTech SE - BNTX PR Newswire - Tue Oct 17, 7:35PM CDT. /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX).Stock Price Forecast. The 16 analysts offering 12-month price forecasts for BioNTech SE have a median target of 124.69, with a high estimate of 264.82 and a low estimate of 98.75. The median ... US09075V1026. BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2 ... BioNTech - BNTX - Stock Price Today - Zacks BioNTech (BNTX) (Delayed Data from NSDQ) $97.16 USD -1.67 (-1.69%) Updated Nov 21, 2023 04:00 PM ET After-Market: $97.18 +0.02 (0.02%) 7:58 PM ET...The share price of BioNTech SE (BNTX) now. What analysts predict: $142.42. 52-week High/Low: $188.99 / $88. 50/200 Day Moving Average: $101.74 / $113.19. This figure corresponds to the Average Price over the previous 50/200 days. For BioNTech stocks, the 50-day moving average is the resistance level today.Cash Amount. Record Date. Pay Date. Jun 2, 2022. $2.111. Jun 3, 2022. Jun 17, 2022. * Dividend amounts are adjusted for stock splits when applicable. Get the latest dividend data for BioNTech SE (BNTX), including dividend history, yield, key dates, growth and other metrics.3 Wall Street analysts have issued twelve-month price objectives for Better Therapeutics' stock. Their BTTX share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 2,791.6% from the stock's current price.BNTX stock analysts projected a per-share loss of 30 cents. BioNTech blamed write-offs to partner Pfizer for the profit and sales hits. On today's stock market, BNTX stock toppled 7.5% to 98.50 ...Nov 6, 2023 · BNTX stock analysts expected 4.44 billion euros in sales for the year. Germany-based BioNTech noted fewer people are receiving primary vaccinations and population-wide boosting is much lower. The stock opened at $102.47, slightly higher than the previous day’s closing price of $102.42. Throughout the day, the stock fluctuated within a range of $98.80 to $102.47. The trading volume for the day was 9,949. BNTX has a market capitalization of $23.2 billion and operates in the Health Technology sector and the Biotechnology industry.In Q3, BioNTech reported total revenues of €895.3m, all derived from COVID vaccine sales, a net profit of €161m, and diluted earnings per share ("EPS") of $0.67. Across the first nine months ...

Medical - Biomedical and Genetics. $23.493B. $18.242B. BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany. Stock Name. Country. Market Cap.See the latest BioNTech SE ADR stock price (BNTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Get the latest BioNTech SE (BNTX) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Instagram:https://instagram. sysco foods stockhealth insurance companies in okcsweet greens stockvanguard consumer staples fund Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany. BNTX - BioNTech SE ADR - Stock screener for investors and traders, financial ... dental insurance plans in tennesseemortgage without 2 years work history 6 Nov 2023 ... ... stock, according to regulatory disclosures. The brothers, who were seed investors in BioNTech, are still the German company's biggest ... can you day trade on webull BioNTech SE stock performance at a glance. Check BioNTech SE’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Over the past 3 months, 5 analysts have published their opinion on BioNTech (NASDAQ:BNTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ...Nov 4, 2021 · Shares of BioNTech (BNTX-1.01%) were 9.1% lower as of 11:51 a.m. EDT on Thursday. The German biotech didn't report any news, so why did its stock slide? ... But stocks that share common ...